Valuation: 3D Signatures Inc

Market Cap 4.02M 2.87M 2.48M 2.31M 2.13M 272M 4.06M 27.19M 10.67M 136M 10.76M 10.53M 452M P/E 2024
-4.87x
P/E 2025 -3.55x
Enterprise Value 3.23M 2.3M 1.99M 1.86M 1.71M 219M 3.26M 21.85M 8.57M 110M 8.65M 8.46M 363M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
97.02%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 67 2026-03-30
Director of Finance/CFO 56 2026-01-29
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 2016-09-07
Director/Board Member - 2022-02-02
Chairman 67 2026-03-30
Change 5-day change 1-year change 3-year change Capi.($)
+32.50%+0.95% - - 3.22M
+0.20%+9.04%+122.62%+260.18% 3.93B
-0.56%-17.16%+84.53%+80.63% 3.71B
-3.38%+28.49%+254.09%+309.91% 2.35B
+1.15%+5.65%-26.06%-34.64% 2.24B
-0.46%-4.82%+57.82%-40.06% 1.94B
-0.31%-2.73%+173.93%-44.26% 946M
+0.36%+10.22%-4.59%+10.87% 898M
-0.73%+1.89%-39.05%-11.75% 513M
+0.24%+22.59%+1.82% - 508M
Average +2.90%+5.96%+69.46%+66.36% 1.89B
Weighted average by Cap. -0.45%+3.77%+93.22%+112.35%

Financials

2024 2025
Net sales - -
Net income -2.71M -1.94M -1.68M -1.56M -1.44M -184M -2.74M -18.36M -7.21M -92.08M -7.27M -7.11M -305M -2.72M -1.94M -1.68M -1.57M -1.44M -184M -2.75M -18.4M -7.22M -92.27M -7.28M -7.12M -306M
Net Debt -796K -568K -492K -458K -422K -53.99M -805K -5.39M -2.11M -27.02M -2.13M -2.09M -89.47M -789K -563K -488K -455K -418K -53.54M -798K -5.34M -2.1M -26.79M -2.11M -2.07M -88.72M
Logo 3D Signatures Inc
Telo Genomics Corp. is a molecular diagnostics company that is engaged in developing the telomere analysis platform Teloview to enable the development of diagnostic and prognostic applications based on the quantification of genomic instability as a disease predictor. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. It quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
Employees
-